Eaton Intelligent Power Limited

Chinese Academy of Sciences

Wigen Biomedicine Technology (shanghai) Co., Ltd.

Santak Electronic (shenzhen) Co., Ltd.

Suzhou Suplead Life Sciences Co., Ltd.

Suzhou Institute of Materia Medica

Cheng Luo

Hualiang Jiang

Han Li

Qiang Chen

Yuanyuan Zhang

Bing Zhou

Jianxiong Yu

Jiajie Duan

Kaixian Chen

Yaxi Yang

Gang Qiao

Liyan Yue

Wei Wan

Yuli Xie

Dawei Zheng

Hualiang Li

Shijie Chen

Zhiyi Yao

Senhao Xiao

Wenshan Deng

Boyu Cui

Xinjun Wang

Huiting Xin

Hong Ding

Dongsheng Li

Bidong Zhang

Zizhou Li

Daohai Du

Lianghe Mei

Wenchao Lu

Shili Wan

Rukang Zhang

The present invention provides a power factor correction circuit, a power factor correction assembly and an on-line uninterruptible power supply including the same. The power factor correction circuit comprises a pulse width modulated rectifier and an isolated DC-DC converter, wherein an output of the pulse width modulated rectifier is connected to an input of the isolated DC-DC converter. The power factor correction assembly comprises a plurality of power factor correction circuits described above, wherein inputs of pulse width modulated rectifiers in the plurality of power factor correction circuits are connected in series, and outputs of isolated DC-DC converters in the plurality of power factor correction circuits are connected in parallel. The power factor correction assembly of the present invention needs no line-frequency transformer and has the advantages of small size, low cost and improved operation reliability.

Power factor correction circuit, power factor correction assembly and on-line uninterruptible power supply comprising same

A ripple control method for a modular cascaded power conversion device is provided. The method obtains, according to a grid voltage vector of three-phase AC power, a second-order fluctuating voltage superposition vector representing the total amount of second-order fluctuating voltages on respective floating DC sides of the three phases; determines a single-phase power control amount of each phase to be transferred from the floating DC sides to a low-voltage DC side; determines a single-module power control amount of each power module to be transferred to a low-voltage DC side thereof; and generates a single-module control signal for controlling the power module, so as to transfer a second-order fluctuating voltage on a floating DC side of the power module to the low-voltage DC side thereof. A modular cascaded power conversion device is also provided.

Ripple control method for modular cascaded power conversion device

The present invention provides an auxiliary pre-charging device for a power converter. The power converter includes at least one power unit with an input end being connected to a medium and high voltage AC power source, and an output end being connected to a low voltage DC bus, wherein the auxiliary pre-charging device includes a switch, a transformer, a pre-charging resistor, and a rectifier sequentially connected in series, one end of the switch is connected to the medium and high voltage AC power source, and an output end of the rectifier is connected to the low voltage DC bus. The present invention also provides a pre-charging method for a power converter, which uses the aforementioned auxiliary pre-charging device to start pre-charging at the low-voltage output end of the power converter.

Auxiliary pre-charging device of power converter, pre-charging method and power converter

Disclosed is a histone acetyltransferase (HAT) inhibitor. Provided are a compound represented by the general formula I, a pharmaceutically acceptable salt, a stereoisomer, an enantiomer, a diastereoisomer, an atropisomer, a racemate, a polymorph, a solvate or an isotope-labeled compound (including deuterium substitution) thereof, a preparation method therefor, a pharmaceutical composition comprising same and use thereof in the treatment of various HAT-related diseases or conditions.

Histone acetyltransferase (HAT) inhibitor and use thereof

The present invention provides a multi-active bridge converter. The converter comprises n multi-active bridges, wherein each of the n multi-active bridges comprises a DC/AC bridge, a single-phase transformer and m AC/DC bridges, where n is greater than or equal to 3, and m is greater than or equal to 1; the single-phase transformer is provided with one primary winding and m secondary windings; the DC/AC bridge is configured to receive a DC input signal, and AC output terminals of the DC/AC bridge are connected to the primary winding of the single-phase transformer; one terminal of the isecondary winding among the m secondary windings of the single-phase transformer is connected to an AC input terminal of the iAC/DC bridge among the m AC/DC bridges, the other terminal of the isecondary winding is connected to the other terminals of the isecondary windings among m secondary windings of single-phase transformers in the remaining (n−1) multi-active bridges, where i is greater than or equal to 1 and less than or equal to m; and positive busbars DC+ and negative busbars DC− of the DC output terminals of all the AC/DC bridges among the n multi-active bridges are respectively connected with each other to serve as DC output terminals of the multi-active bridge converter.

Multi-active bridge (MAB) converter and control method thereof and power conversion device

The present invention provides a power factor correction circuit (), a power factor correction assembly () and an on-line uninterruptible power supply including the same. The power factor correction circuit () comprises a pulse width modulated rectifier () and an isolated DC-DC converter (), wherein an output of the pulse width modulated rectifier () is connected to an input of the isolated DC-DC converter (). The power factor correction assembly () comprises a plurality of power factor correction circuits () described above, wherein inputs of pulse width modulated rectifiers () in the plurality of power factor correction circuits () are connected in series, and outputs of isolated DC-DC converters () in the plurality of power factor correction circuits () are connected in parallel. The power factor correction assembly () of the present invention needs no line-frequency transformer and has the advantages of small size, low cost and improved operation reliability.

The present invention provides a Pulse Width Modulation (PWM) method for a Cascaded H-bridge (CHB) converter. Each phase of the converter is provided with n Cascaded H-bridge rectifier circuits, or may also be provided with n Cascaded H-bridge rectifier circuits+1 redundant H-bridge rectifier circuit. The method includes following steps of: S1, generating groups of sinusoidal signals as reference waveforms, and generating n carrier signals having sequentially decreasing levels and equal amplitudes to correspond to the H-bridge rectifier circuit at the first to the nlevels, where the levels of the n carrier signals are cascaded to fill the voltage amplitude of a unipolar half cycle of the reference waveform; and S2, determining PWM signals for controlling power transistors of the corresponding H-bridge rectifier circuits based on each reference waveform and each carrier signal. According to the present invention, the CHB converter allows the MV grid to be directly coupled with a LV side without a conventional transformer, which reduces the heat loss and balances the distribution of heat loss between the power transistors and between the H-bridges at all levels, thus prolonging the service life.

Pulse Width Modulation method for Cascaded H-bridge converter

Harmonic actuator

Robot caster

The present invention relates to use of an aminomethylenecyclohexane-1,3-dione compound, more particularly to use of a compound shown in the following formula (I) or a pharmaceutically acceptable salt thereof alone or in combination with other drug in preparing a drug for regulating or treating a disease related to autophagy, especially mammalian ATG8 homologous proteins. 

Use of aminomethylenecyclohexane-1,3-dione compound

The present invention relates to a bromodomain inhibitor. Provided are a compound represented by general formula I or a pharmaceutically acceptable salt, enantiomer, diastereomer, atropisomer, racemate, polymorph, solvate, or isotopically labeled compound (including deuterium substitution) thereof, a preparation method of the same, a pharmaceutical composition comprising the same, and a pharmaceutical use thereof. 

Bromodomain inhibitor compound and use thereof

It is related to compounds used as autophagy modulators and a method for preparing and using the same, specifically providing a compound of general formula (I), or pharmaceutically acceptable salts thereof, which is a type of autophagy modulators, particularly mammalian ATG8 homologues modulators. 

Compound used as autophagy regulator, and preparation method therefor and uses thereof

The present invention provides an isoindolone-imide ring-1,3-dione-2-ene compound, and a preparation method, a pharmaceutical composition and use thereof. Specifically, the present invention provides a compound of Formula (I) below or a pharmaceutically acceptable salt thereof, wherein Ar is an isoindolinone-imide group represented by Formula (II), L is absent or is a divalent, trivalent or tetravalent linking group, and X is a group represented by Formula (III). Definitions of the other groups are as described in the specification. The compound of Formula (I) is an autophagy modulators, particularly a mammalian ATG8 homolog modulator. 

Class of isoindolone-imide ring-1,3-dione-2-ene compounds, composition and use thereof

The present invention provides a compound represented by formula I, pharmaceutically acceptable salts, enantiomers, diastereomers or racemates thereof, the preparation method thereof, the pharmaceutical composition comprising the same, and the use thereof in the preparation of a medicament for treating a disease or condition mediated by EED and/or PRC2. The compound of the present invention can be used treating PRC2-mediated diseases or conditions. 

Triazolopyrimidine, triazolopyridine compounds, and the composition thereof for treating PRC2-mediated diseases

Growing community of inventors

Shanghai, China

Cheng Luo